ClinicalTrialsFinder

HER2 Overexpression Clinical Trials in Nashville, Tennessee

1 recruitingNashville, Tennessee

Showing 1–1 of 1 trials

Recruiting
Phase 1

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

Advanced Solid Tumor, AdultERBB2 Altered Breast CancerERBB2 Gene Amplification+1 more
Cogent Biosciences, Inc.100 enrolled6 locationsNCT07361562